A1腺受体的上调伴随着心肌腺水平的降低,在患有左心室功能障碍的小鼠中
Hajime Funakoshi1, Lefteris C Zacharia, Zhonghua Tang
1Center for Translational Medicine, Department of Medicine, Jefferson Medical College, Philadelphia, PA 19107, USA.
Circulation
|April 18, 2007
概括
左心室功能障碍的心力衰竭与较低的腺水平和改变的腺受体 (AR) 表达有关. 向腺系统可能提供新的心力衰竭疗法.
科学领域:
- 心血管生理学心血管生理学
- 分子心脏病学分子心脏病学
- 心脏衰竭病理生理学 病理生理学
背景情况:
- 已知腺素可以在缺血/再输血期间保护心脏.
- 在扩张和功能障碍的心脏中,腺氨酸-腺氨酸受体 (AR) 途径的作用不太清楚.
- 瘤坏死因子-α (TNF) 的过度表达会导致左心室缩功能障碍.
研究的目的:
- 在心力衰竭的小鼠模型中调查腺水平和AR表达.
- 确定观察到的变化是否与TNF过度表达特异,或是心脏功能障碍的后果.
主要方法:
- 在过度表达TNF的转基因小鼠中评估了腺水平和AR表达.
- 与其他心力衰竭模型 (卡尔西克斯特林过度表达,慢性压力过载) 进行比较.
- 使用选择性激动剂评估AR变化的生理意义.
主要成果:
- 过度表达TNF的小鼠显示心脏腺素水平显著降低.
- A1-AR水平大幅上升,而A2A-AR水平下降.
- 增强的A1-AR反应性证实了这些变化的生理相关性.
结论:
- 无论原因如何 (TNF,calsequestrin,压力过载),心脏功能障碍与心肌腺和AR水平的改变有关.
- 心肌腺系统代表了心力衰竭的潜在治疗点.
相关概念视频
Adrenergic Receptors: ɑ Subtype
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Receptors: β Subtype
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...


